Brian Brightman
Optometrist · Lincoln, NENPI 1407876600
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 66.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $5,538 and has fallen 56.8% since, to $2,391 in 2025. Among optometrist clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $93.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Coopervision Inc.$1K
- Bausch & Lomb Americas Inc.$852
- Alcon$811
- Johnson & Johnson Vision Care, Inc.$791
- Sun Pharmaceutical Industries Inc.$650
- plus $1K from 11 others
What the payments were for
- Consulting fees$9806%
- Speaking & faculty fees$9,61958%
- Travel & lodging$5573%
- Food & beverage$5,31432%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $10,918 |
| Coopervision Inc. | 7 | $1,110 |
| Bausch & Lomb Americas Inc. | 17 | $852 |
| Alcon | 16 | $811 |
| Johnson & Johnson Vision Care, Inc. | 27 | $791 |
| Sun Pharmaceutical Industries Inc. | 20 | $650 |
| Oyster Point Pharma, Inc. | 21 | $380 |
| Dompe US, Inc. | 5 | $227 |
| Glaukos Corporation | 1 | $193 |
| Amgen | 3 | $176 |
| Tarsus Pharmaceuticals, Inc. | 3 | $97 |
| Novartis | 6 | $96 |
| Kala Pharmaceuticals, Inc. | 3 | $80 |
| Rxsight Inc | 1 | $42 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $36 |
| Shire North American Group Inc | 1 | $16 |
| Sight Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS$7,650
- RESTASIS MULTIDOSE$2,819
- Proclear Contact Lens$960
- Precision7$240
- Photrexa Viscous and Photrexa$193
- XIIDRA$143
- MIEBO$125
- INFUSE$120
- TOTAL30$104
- CEQUA$103
How this compares
$16,488 in reported general payments places this provider in the 95th percentile of 383 optometrist providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 66 | $67,469 |
| MieboPerfluorohexyloctane/Pf | 23 | $22,531 |
| LumiganBimatoprost | 25 | $13,737 |
| Cyclosporine | 13 | $3,254 |
| Travoprost | 17 | $2,104 |
| Prednisolone Acetate | 29 | $1,219 |
| Latanoprost | 183 | $1,198 |
| Levobunolol Hcl | 47 | $965 |
| Timolol Maleate | 33 | $416 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $393 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 25 | $235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $10,918 | $81,20691 claims |
| Bausch & Lomb Americas Inc.Miebo | $852 | $22,53123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 383 optometrist providers in Nebraska.
Other optometrist in Lincoln
- William GeisertLincoln$6K
- Tyler LeeLincoln$4K
- Jonathan KnutsonLincoln$3K
- Lynda TranLincoln$2K
- Christopher WolfeOmaha$154K
- Cheryl ChapmanGretna$13K
- Jeffrey KleinNorfolk$12K
- Mark ToelleOmaha$10K
- John GoertzOmaha$8K
- Andrea CardaPlattsmouth$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.